TY  - JOUR
A1  - Leyh, Catherine
A1  - Ehmer, Ursula
A1  - Roessler, Daniel
A1  - Philipp, Alexander B.
A1  - Reiter, Florian P.
A1  - Jeliazkova, Petia
A1  - Jochheim, Leonie S.
A1  - Jeschke, Matthias
A1  - Hammig, Janina
A1  - Ludwig, Johannes M.
A1  - Theysohn, Jens M.
A1  - Geier, Andreas
A1  - Lange, Christian M.
T1  - Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
JF  - Cancers
N2  - The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared in a retrospective real-world cohort. In total, 164 patients with HCC were included. Child B cirrhosis was present in 26 patients (16.5%), whereas 132 patients (83.5%) had preserved liver function. In total, 72 patients (44%) discontinued systemic therapy after first-line therapy while 51 (31%) and 31 (19%) patients received 2 or more treatment lines. Most notably, median overall survival (mOS) was influenced by liver functional status and patient performance status at the beginning of first-line therapy. Patients receiving a sequential therapy regimen had significantly longer mOS compared to patients that discontinued systemic therapy after omitting first-line treatment. The choice of the initial TKI did not impact mOS. A clear deterioration of liver function could be observed during the course of TKI-based treatment.
KW  - hepatocellular carcinoma
KW  - systemic therapy
KW  - tyrosine-kinase inhibitor
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270765
SN  - 2072-6694
VL  - 14
IS  - 8
ER  - 
TY  - JOUR
A1  - Schneider, Leon N.
A1  - Tanzer Krauel, Eva-Maria
A1  - Deutsch, Carl
A1  - Urbahns, Klaus
A1  - Bischof, Tobias
A1  - Maibom, Kristina A. M.
A1  - Landmann, Johannes
A1  - Keppner, Fabian
A1  - Kerpen, Christoph
A1  - Hailmann, Michael
A1  - Zapf, Ludwig
A1  - Knuplez, Tanja
A1  - Bertermann, Rüdiger
A1  - Ignat'ev, Nikolai V.
A1  - Finze, Maik
T1  - Stable and Storable N(CF\(_{3}\))\(_{2}\) Transfer Reagents
JF  - Chemistry—A European Journal
N2  - Fluorinated groups are essential for drug design, agrochemicals, and materials science. The bis(trifluoromethyl)amino group is an example of a stable group that has a high potential. While the number of molecules containing perfluoroalkyl, perfluoroalkoxy, and other fluorinated groups is steadily increasing, examples with the N(CF\(_{3}\))\(_{2}\) group are rare. One reason is that transfer reagents are scarce and metal-based storable reagents are unknown. Herein, a set of Cu\(^{I}\) and Ag\(^{I}\) bis(trifluoromethyl)amido complexes stabilized by N- and P-donor ligands with unprecedented stability are presented. The complexes are stable solids that can even be manipulated in air for a short time. They are bis(trifluoromethyl)amination reagents as shown by nucleophilic substitution and Sandmeyer reactions. In addition to a series of benzylbis(trifluoromethyl)amines, 2-bis(trifluoromethyl)amino acetate was obtained, which, upon hydrolysis, gives the fluorinated amino acid N,N-bis(trifluoromethyl)glycine.
KW  - silver
KW  - amination
KW  - copper
KW  - fluorinated ligands
KW  - N ligands
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-256890
VL  - 27
IS  - 42
ER  -